Practical Considerations for Using CCK-8 in Cell Proliferation and Cytotoxicity Assays

Overview

Cell Counting Kit-8 (CCK-8) uses the WST-8 tetrazolium salt, which is reduced by cellular dehydrogenases (via NAD(P)H-dependent electron transfer) to a water-soluble formazan dye. The formazan accumulates in the medium and is quantified by absorbance at 450 nm (often with a reference at 650–690 nm). Because the product is soluble, no solubilization step is required, enabling higher throughput, better linearity at low cell numbers, and easier multiplexing than MTT/XTT.

Typical readout:

• Add 10 µL CCK-8 to 100 µL culture medium per well of a 96-well plate (1:10 v/v).

• Incubate 0.5–4 h at 37 °C, 5% CO₂ (optimize).

• Measure A450 (optional reference A650–690).

Common Experimental Uses

1) Proliferation (growth curves, mitogen response)

• Goal: Track changes in viable cell number over time after treatment (growth factors, siRNA, media changes).

• Design: Seed a low starting density to keep values within linear range across multiple time points (e.g., Day 0, 1, 2, 3).

• Readout: Plot A450 vs time or normalize to Day 0 for fold-change.

2) Viability (metabolic competence under stress)

• Goal: Quantify viable/metabolically active cells after exposure (hypoxia, nutrient deprivation).

• Design: Single time-point read at a fixed exposure duration (e.g., 24 h).

• Readout: %Viability relative to untreated control.

3) Cytotoxicity / IC₅₀ Determination (drug screens)

• Goal: Generate dose–response to compute IC₅₀/EC₅₀.

• Design: 8–12 concentrations, 1:3 or 1:2 serial dilutions, biological triplicates.

• Readout: Fit 4-parameter logistic (4PL) to %viability vs log[dose].

Technical Basis & Sensitivity vs MTT/XTT

• WST-8 reduction site: Occurs extracellularly at the cell surface via electron mediators; the formazan stays in the medium (contrast: MTT formazan precipitates inside cells).

• Sensitivity:

  • CCK-8 ≥ XTT > MTT for low cell numbers due to higher extinction coefficient and no solubilization variability.

  • Typical linear detection down to ~500–1,000 adherent cells/well (96-well); for some lines down to ~200–300 with longer incubation.

• Precision: Eliminating the solubilization step (required for MTT) reduces well-to-well CV and operator bias.

• Non-destructive enough for follow-up: After short incubations, many lines tolerate media replacement and downstream assays (qPCR, imaging). Validate for your cell type.

Assay Setup: Best Practices

A) Plate Format, Volume, and Pathlength

• 96-well: 100 µL medium + 10 µL CCK-8; pathlength ~0.55–0.65 cm.

• 384-well: 25–50 µL medium + 2.5–5 µL CCK-8; pathlength ~0.25–0.35 cm.

• Keep fill volume consistent to maintain pathlength and linearity.

B) Seeding Density (starting points to optimize)

Adherent cells (96-well, measure at 24–48 h):

• Fast-growing (e.g., HeLa, HEK293): 1–3 × 10³ cells/well.

• Moderate (e.g., A549, MCF-7): 3–8 × 10³ cells/well.

• Slow/primary: 8–20 × 10³ cells/well.

Suspension cells:

• 5–15 × 10³ cells/well (96-well), then briefly spin 200 × g, 3–5 min (optional) to reduce sampling error before adding CCK-8.

Guideline: Choose a density that yields A450 of 0.2–1.5 after your intended incubation. Keep all groups in the linear segment of the standard curve.

C) Incubation Time with CCK-8

• Start with 1–2 h; extend to 3–4 h for low cell numbers.

• Do not exceed times that push controls beyond linear range (plateaus distort quantitation).

• Maintain identical timing across plates when comparing groups.

D) Media Composition & Interferences

• Phenol red: Minimal at 450 nm, but include media-only blanks.

• Serum: Usually fine (1–10% FBS). Keep constant across groups.

• Reducing agents/antioxidants (e.g., ascorbate, high NAC), highly colored compounds, and strong redox drugs can bias readings. Include compound-only controls (no cells + CCK-8).

• Avoid bubbles; tap gently or briefly spin to clear.

E) Controls & Plate Layout

• Blank: Medium + CCK-8 (no cells).

• NTC (compound-only): Medium + compound + CCK-8 (no cells).

• Vehicle control: Cells + vehicle + CCK-8.

• Positive kill control: Cells + cytotoxin (e.g., 10% DMSO for 10 min, then wash/replace).

• Edge wells: Fill with PBS or medium to reduce evaporation; use inner wells for samples.

Data Acquisition & Calculations

Basic Formulas

• Background-corrected absorbance:
  A\*=A450−ArefA^\* = A_{450} – A_{ref}A\*=A450​−Aref​ (optional Aref=650–690A_{ref}=650–690Aref​=650–690 nm)
  or simply subtract the Blank well value from each reading.

• % Viability (relative to vehicle control):

  % Viability=Atreated\*−Ablank\*Avehicle\*−Ablank\*×100\%\,\text{Viability} = \frac{A^\*_{\text{treated}} – A^\*_{\text{blank}}}{A^\*_{\text{vehicle}} – A^\*_{\text{blank}}} \times 100%Viability=Avehicle\*​−Ablank\*​Atreated\*​−Ablank\*​​×100

• Z′-factor (assay quality for screens):

  Z′=1−3(σpos+σneg)∣μpos−μneg∣Z’ = 1 – \frac{3(\sigma_{pos} + \sigma_{neg})}{|\mu_{pos} – \mu_{neg}|}Z′=1−∣μpos​−μneg​∣3(σpos​+σneg​)​

  Aim for Z′ ≥ 0.5.

Standard/Linearity Check

• Seed a 2-fold cell series (e.g., 0.5, 1, 2, 4, 8, 16 × 10³ cells/well).

• Plot A450 vs cell number; R² ≥ 0.98 in your working window.

• Choose seeding/CCK-8 time that centers your experimental groups in this linear window.

Dose–Response Fitting (IC₅₀)

• Use 4-parameter logistic (4PL) with bottom/top constraints from kill and vehicle controls.

• Replicates: at least n = 3 wells per concentration; biological ≥ 3 recommended.

Troubleshooting & Artifacts

Symptom → Likely Cause → Fix

• Low signal in all wells → Short incubation, low cell number, cold reagent → Warm CCK-8 to RT, extend to 3 h, increase seeding.

• High background (blanks > 0.15–0.2 A.U.) → Colored medium/compounds, light exposure → Use reference wavelength; include compound-only blanks; protect from light.

• Non-linear at high density → Signal plateau; nutrient depletion → Reduce incubation time or seeding density.

• Edge effects → Evaporation, temperature gradients → Use humidified chambers, fill edge wells with buffer, equilibrate plate on shaker briefly.

• Apparent “toxicity” but confluence normal → Drug reduces metabolic rate (not cell number) → Confirm with orthogonal assay (DNA content, nuclei count).

• Suspension cells: high CV → Cells float or clump → Pre-coat plates (poly-L-lysine), gentle spin before read, add 0.5–1% methylcellulose if compatible.

Comparing CCK-8 to MTT/XTT

Bottom line: CCK-8 typically delivers better sensitivity and precision with simpler workflows than MTT/XTT, especially valuable for low-abundance cells, primary cultures, and miniaturized screens.

Application-Specific Notes

High-Throughput Drug Screens

• Use shorter CCK-8 incubation (0.5–2 h) to avoid time-dependent shifts unrelated to drug effect.

• Batch controls across plates; include inter-plate controls to track drift.

• Automate edge-well buffering and timed reagent additions.

Primary Cells / Low Metabolism Lines

• Expect slower WST-8 reduction; plan longer incubation and slightly higher seeding.

• Validate linearity carefully; consider combining with DNA-binding fluorescent assays for orthogonal normalization.

Suspension / Hematopoietic Lines

• Reduce variability with brief spins and uniform mixing before reading.

• If compounds lyse cells, debris can scatter light—use reference wavelength and confirm with trypan blue or flow cytometry.

Serum-Free or Defined Media

• Redox environment can change markedly; re-optimize incubation time and verify blanks.

Quality Control & Documentation Checklist

• Calibrate reader for A450 (and reference channel).

• Pre-run linearity seeding series each new cell line or medium.

• Fix seeding density, volume, incubation time for all comparative runs.

• Include Blank, Vehicle, Compound-only, Positive kill controls.

• Ensure R² ≥ 0.98 in working range; maintain CV ≤ 10% per group.

• Monitor Z′-factor ≥ 0.5 in screening plates.

• Archive raw A450, background, and calculation sheets for traceability.

Example 96-Well Starter Protocol (Adherent Cells)

1. Day −1: Seed 3,000 cells/well in 100 µL complete medium.

2. Day 0: Treat with compounds (final DMSO ≤ 0.1%).

3. Day 1 (24 h): Add 10 µL CCK-8/well. Incubate 90 min.

4. Read: A450 (reference 650 nm).

5. Compute: Background-corrected A, %Viability vs vehicle, 4PL fit for IC₅₀.

Adjust cell number and incubation time so vehicle wells yield A450 ≈ 0.6–1.0 for best dynamic range.

Reporting Recommendations (for reproducibility/SEO)

• Cell line/authentication, passage number.

• Plate format, seeding density, media composition, serum %.

• Incubation time with CCK-8, temperature/CO₂.

• Plate reader make/model, wavelengths, pathlength correction (if used).

• Controls (blank, vehicle, positive kill), n and N.

• Linearity metrics (slope, R²), Z′-factor (for screens).

• Statistics: curve fitting method (4PL), constraints, CI on IC₅₀.